Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer

Makhoul Issam; Klimberg Vicki Suzanne; Korourian Soheila; Henry-Tillman Ronda S.; Siegel Eric R.; Westbrook Kent C.; Hutchins Laura F.

首页> 外文期刊>American Journal of Clinical Oncology: Cancer Clinical Trials >Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer

【24h】

Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer

机译：新辅助化疗与贝伐单抗联合可改善激素受体阴性可手术或局部晚期乳腺癌患者的病理完全缓解

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives: To evaluate the pathologic complete response (pCR) and safety of bevacizumab (B) with chemotherapy in the neoadjuvant setting of breast cancer (BC).

机译：目的：评估贝伐单抗（B）在乳腺癌（BC）新辅助治疗中的化学疗法的病理完全反应（pCR）和安全性。

著录项

来源
《American Journal of Clinical Oncology: Cancer Clinical Trials》 |2015年第1期|共6页
作者
Makhoul Issam; Klimberg Vicki Suzanne; Korourian Soheila; Henry-Tillman Ronda S.; Siegel Eric R.; Westbrook Kent C.; Hutchins Laura F.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
breast cancer; neoadjuvant chemotherapy; antiangiogenic therapy; bevacizumab; pathologic complete response;

机译：乳腺癌;新辅助化疗;抗血管生成治疗;贝伐单抗;病理完全缓解;

相似文献

外文文献
中文文献
专利

1. Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer [J] . Makhoul Issam, Klimberg Vicki Suzanne, Korourian Soheila, American Journal of Clinical Oncology: Cancer Clinical Trials . 2015,第1期

机译：新辅助化疗与贝伐单抗联合可改善激素受体阴性可手术或局部晚期乳腺癌患者的病理完全缓解
2. Clinical and Pathological Response to Neoadjuvant Chemotherapy Based on Primary Tumor Reduction is Correlated to Survival in Hormone Receptor-Positive but not Hormone Receptor-Negative Locally Advanced Breast Cancer [J] . Chen Sheng, Liu Yin, Ouyang Qian-Wen, Annals of surgical oncology . 2015,第1期

机译：基于原发性肿瘤减少的新辅助化疗的临床和病理反应与激素受体阳性而非激素受体阴性的局部晚期乳腺癌的存活率相关
3. Clinical and Pathological Response to Neoadjuvant Chemotherapy Based on Primary Tumor Reduction is Correlated to Survival in Hormone Receptor-Positive but not Hormone Receptor-Negative Locally Advanced Breast Cancer [J] . Chen Sheng, Liu Yin, Ouyang Qian-Wen, Annals of surgical oncology . 2015,第1期

机译：基于原发性肿瘤减少的Neoadjuvant化疗的临床和病理反应与激素受体阳性的生存存在相关，但不是激素受体 - 负局部晚期乳腺癌
4. Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using Deep Learning with Integrative Imaging, Molecular and Demographic Data [C] . Hongyi Duanmu, Pauline Boning Huang, Srinidhi Brahmavar, International Conference on Medical Image Computing and Computer-Assisted Intervention . 2020

机译：利用综合成像，分子和人口统计数据预测对乳腺癌新辅助化疗的病理完全反应
5. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
6. A case report of locally advanced triple negative breast cancer showing pathological complete response to weekly paclitaxel with bevacizumab treatment following disease progression during anthracycline-based neoadjuvant chemotherapy [O] . Hideo Shigematsu, Shinji Ozaki, Daisuke Yasui, 2017

机译：在基于蒽环类新辅助化疗期间疾病进展后局部晚期三阴性乳腺癌显示出对每周紫杉醇联合贝伐单抗治疗的病理完全反应的病例报告
7. A case report of locally advanced triple negative breast cancer showing pathological complete response to weekly paclitaxel with bevacizumab treatment following disease progression during anthracycline-based neoadjuvant chemotherapy [O] . Hideo Shigematsu, Shinji Ozaki, Daisuke Yasui, 2017

机译：局部晚期三阴性乳腺癌的病例报告显示，在基于蒽环类的新辅助化疗期间疾病进展后，每周紫杉醇与贝伐单抗治疗的病理完全反应

Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer

摘要

著录项

相似文献

相关主题

期刊订阅